Introduction {#s1}
============

Asthma is a common chronic disorder of the airways, which is characterized by airway hyperresponsiveness, obstruction, and airway wall remodeling [@pone.0101861-Kudo1]. Based on data from World Health Survey, To T and colleagues found that the global prevalence of doctor-diagnosed asthma in adults was estimated at 4.3% [@pone.0101861-To1]. The prevalence reported in several studies indicated that asthma may still be increasing in western countries and developing countries [@pone.0101861-To1]--[@pone.0101861-Yangzong1]. Asthma is a complex disease and has a strong genetic component in its pathogenesis. So far, considerable efforts have been made to evaluate the association between genetic variants and asthma risk, and numerous genes have been identified as asthma susceptible genes [@pone.0101861-Martinez1]--[@pone.0101861-Vercelli1].

The β2-adrenoceptor (β2AR) mediates the physiological responses in the airway, which include bronchodilation, bronchoprotection, enhanced mucociliary clearance [@pone.0101861-Devalia1]. The β2AR gene is located on chromosome 5q31-q32, a region that is genetically linked to asthma and related phenotypes [@pone.0101861-Postma1]. There are three best-known polymorphisms in the coding region of the β2AR gene that can modulate the function of the receptor [@pone.0101861-Green1]. Many studies have investigated these polymorphisms to assess their potential contributions to the risk of asthma. It was observed in some studies that β2AR gene may play a significant role in the pathogenesis of asthma [@pone.0101861-Kotani1]--[@pone.0101861-Bhatnagar1]. However, other studies showed no association between asthma and β2AR gene polymorphisms [@pone.0101861-Potter1]--[@pone.0101861-Lin1]. A large population-based study and three meta-analyses have also shown inconsistent results [@pone.0101861-Thakkinstian1]--[@pone.0101861-Migita1]. Since then, additional many studies with large sample sizes about β2AR polymorphisms on asthma risk have been reported.

Therefore, we present the results of a comprehensively updated meta-analysis of all relevant published data to investigate the association between β2AR gene polymorphisms and asthma risk with focus on Arg/Gly16 and Gln/Glu27 polymorphism.

Materials and Methods {#s2}
=====================

Publication search {#s2a}
------------------

We followed criteria of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) to perform this meta-analysis ([Dox S1](#pone.0101861.s003){ref-type="supplementary-material"}). Two investigators (H.X. and Y.H.) independently carried out a systematic search of the PubMed, EMBASE, BIOSIS Previews databases for articles published until 3 January, 2014 to identify potentially relevant articles. The search strategy utilized in our study were as follows: "asthma or bronchial asthma or bronchial hyperreactivity or allergy or atopy*"* and *"ADRB2* or β2-adrenergic or beta adrenergic or adrenergic or adrenoceptor or beta2 AR*"* and "polymorphism\* or variant\* or genetic\* or mutant\*". No publication language restrictions were imposed. All the searchable studies were retrieved, and we also checked their references for other relevant publications. The detailed search strategy for this study is showed in [Dox S2](#pone.0101861.s004){ref-type="supplementary-material"}.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

The inclusion criteria of our study were as follows: (1) Human studies evaluating associations between β~2~-Adrenoceptor gene polymorphisms and asthma risk, (2) There were at least two comparison groups, for example, asthma versus control (nonasthma) group, and (3) Genotype distributions in comparison groups should be available for estimating an odds ratio (OR) with 95% confidence interval (CI). Studies would be discarded if they met one of the following criteria: (1) Not relevant to β~2~-Adrenoceptor polymorphisms or asthma risk, (2) The design based on family or sibling pairs, (3) Reviews or abstracts without useful information. If the same patient population was reported in several publications, we included the most complete study in our meta-analysis. If original genotype frequency data were not reported, we sent an email to the corresponding author for additional data. Studies were excluded from our meta-analysis if their authors did not provide us with related data.

Data Extraction {#s2c}
---------------

In the data collection process, two investigators (H.X. and Y.H.) independently examined full manuscripts of eligible studies, and relevant data were extracted into predesigned data collection form. We verified accuracy of data by comparing collection forms from each investigator. Any disagreement was resolved by discussion, or a third author (Y.C.) would evaluate these articles. The following information was collected from each eligible study: first author\'s name, year of publication, original country, ethnicity, sample size, genotyping method, age, and genotype numbers in cases and controls.

Publication Bias {#s2d}
----------------

Publication bias of studies was assessed using funnel plot, and P\<0.05 was considered statistically significant. In addition, publication bias was also evaluated via Egger's linear regression test.

Statistical analysis {#s2e}
--------------------

We tested the Hardy-Weinberg equilibrium (HWE) in control group using the Chi-square test. The pooled ORs were calculated for allelic genetic model, additive genetic model, dominant genetic model and recessive genetic model, respectively. Subgroup analyses were performed in term of ethnicity and age. The heterogeneity between the studies was investigated by using Cochrane Q-test. I^2^ was also used to test the heterogeneity among the included studies. A p value\>0.10 for the Q-test indicates a lack of heterogeneity among the studies, then the pooled OR estimate of each study was calculated by the fixed effect model. Otherwise, the random effect model was used.

Statistical analyses were performed using the Revman5.2 software (Nordic Cochrane Center, Copenhagen, Denmark), STATA 12.0 software (Stata Corporation, College Station, TX). A p value\<0.05 was considered statistically significant, except for test of heterogeneity where a level of p value\<0.10 was used.

Results {#s3}
=======

Characteristics of studies included in the Meta-analysis {#s3a}
--------------------------------------------------------

The flow chart in [Figure 1](#pone-0101861-g001){ref-type="fig"} outlined the study selection process. A total of 2205 articles were identified at the initial search. 730 duplicated studies were eliminated first. After reading the abstracts and titles, 1320 articles were subsequently excluded. The remaining 155 articles were then assessed for inclusion and 120 articles were excluded (98 records excluded for irrelevance, 15 records no detailed genotypes, 4 depart from HWE, 3 duplicate publications). In this process, study references were checked as well and 2 relevant publication were identified [@pone.0101861-Hakonarson1], [@pone.0101861-Chan1]. Finally, a total of 37 studies met the inclusion criteria, and were included in the meta-analysis [@pone.0101861-Kotani1]--[@pone.0101861-Lin1], . These eligible studies contained 6648 asthma cases and 15943 controls, and 11 Caucasian, 18 Asian and 8 other populations. The distributions of the β2AR gene polymorphism in normal controls were consistent with HWE in every study. Details of each study included in this meta-analysis were summarized in [Table 1](#pone-0101861-t001){ref-type="table"}.

![Flow Diagram for Inclusion of Studies in Meta-analysis.\
The initial search identified 2205 articles, of which, 37 were included in the final analysis.](pone.0101861.g001){#pone-0101861-g001}

10.1371/journal.pone.0101861.t001

###### Characteristics of studies included in meta-analysis.

![](pone.0101861.t001){#pone-0101861-t001-1}

  First author\[Ref\]    Year     Country      Ethnicity   Case (n)   Control (n)   Study design    Age group   GenotypingMethod
  --------------------- ------ -------------- ----------- ---------- ------------- --------------- ----------- -------------------
  Abdul Vahab Saadi\#    2013      India         Asian       150          150       Case-control      Mixed        Sequencing
  Al-Rubaish A\#         2011   Saudi Arabia    Arabia        73          85        Case-control    Children        PCR-RFLP
  Barr RG\#              2001       USA        Caucasian     171          137       Case-control     Adults      Allele specific
  Bhatnagar, P \#        2005      India         Asian       101          55        Case-control     Adults        Sequencing
  Binaei S\#             2003       USA        Caucasian      38          155       Case-control    Children        PCR-RFLP
  Birbian N\#            2012      India         Asian       410          414       Case-control     Adults         PCR-RFLP
  Chan IH\#              2008      China         Asian       295          173       Case-control    Children        PCR-RFLP
  ChiangCH\#             2012      China         Asian       476          115       Case-control     Adults         PCR-RFLP
  Dewar JC\#             1998        UK        Caucasian     117          511       Cross-section    Adults      Allele specific
  Gao G\#                2000      China         Asian        58          89        Case-control     Adults         PCR-RFLP
  Gao JM\#               2002      China         Asian       125          96        Case-control     Adults         PCR-RFLP
  Hakonarson H\#         2001     Iceland      Caucasian     324          199       Case-control     Adults        Sequencing
  Holloway JW\#          2000   New Zealand    Caucasian     154          91        Case-control     Adults        Sequencing
  Hopes E\#              1998        UK        Caucasian     102          317       Cross-section   Children     Allele specific
  Isaza C\#              2012     Colombia        NA         109          137       Case-control    Children       Sequencing
  Karam RA\#             2013      Egypt        African       90          110       Case-control    Children     Allele specific
  Kohyama K\#            2011      Japan         Asian       300          100       Case-control     Adults        Sequencing
  Kotani Y\#             1999      Japan         Asian       117          103       Case-control     Adults      Allele specific
  Leung TF\#             2002      China         Asian        76          70        Case-control    Children        PCR-RFLP
  Li H\#                 2009      China         Asian       192          192                       Children        PCR-RFLP
  Lin YC\#               2003      China         Asian        80          69        Case-control    Children     Allele specific
  Martinez FD\#          1997       USA        Caucasian      38          229       Cross-section   Children        PCR-RFLP
  Matheson MC\#          2006    Australia     Caucasian     123          221       Case-control     Adults           ARMS
  Munakata M\#           2006      Japan         Asian        46          100       Case-control       NA          Sequencing
  Pino-Yanes M\#         2013      Spain       Hispanic      596         1240       Case-control    Children    iPLEXH Gold assay
  Potter PC\#            1993   South Africa    African       22          30        Case-control    Children        PCR-RFLP
  Qiu YY\#               2010      China         Asian       201          276       Case-control     Adults        Sequencing
  Reihsaus E\#           1993       USA           NA          51          56        Case-control     Adults        Sequencing
  Santillan AA\#         2003      Mexico         NA         303          604       Case-control     Adults         PCR-RFLP
  Shachor J\#            2003      Israel       Arabia        66          113       Case-control     Adults         PCR-RFLP
  Szczepankiewicz A\#    2009      Poland      Caucasian     113          121       Case-control    Children        PCR-RFLP
  Tatarskyy, P.F \#      2011     Ukraine      Caucasian     114          86        Case-control    Children     Multiplexed PCR
  Thomsen M\#            2012     Denmark      Caucasian     547         8386       Cross-section    Adults         PCR-RFLP
  Wang JY\#              2009      China         Asian       442          545       Case-control    Children         Taq Man
  Wang Z\#               2001      China         Asian       128          136       Case-control     Adults      Allele specific
  Ye, Y.M\#              2010      Korea         Asian       102          322       Case-control     Adults        Sequencing
  Zheng, B.Q\#           2012      China         Asian       198          110       Case-control    Children       Sequencing

NA, not available; PCR, polymerase chain reaction; RFLP, restricted fragment length polymorphisms; SSP, sequence.

-specific primers; SPT, skin prick test; BHR,bronchial hyperresponsiveness; TDI, toluene diisocyanate; ARMS, amplification refractory mutation system;Mixed, participants involved children and adults.

β2AR Arg/Gly16 and Asthma Risk {#s3b}
------------------------------

Among 37 studies included in the meta-analysis, 29 investigated the contribution of β2AR Arg/Gly16 polymorphism to asthma risk ([Table S1](#pone.0101861.s001){ref-type="supplementary-material"}). Overall, slightly significant associations were found in allelic genetic model (OR = 1.06, 95% CI = 1.01∼1.12, p = 0.02), additive genetic model (OR = 1.11, 95% CI = 1.02∼1.21, p = 0.02) for Arg/Gly16. Stratified by ethnicity, significant associations were also found in Asian population in allelic genetic model (OR = 1.14, 95% CI = 1.05∼1.23, p = 0.001), recessive genetic model (OR = 1.26, 95% CI = 1.12∼1.43, p = 008) and additive model (OR = 1.23, 95% CI = 1.06∼1.44, p = 0001), but not in Caucasian population. No association was found in adults and children subgroup in term of age ([Table 2](#pone-0101861-t002){ref-type="table"}).

10.1371/journal.pone.0101861.t002

###### Results of the pooled analyses and subgroup analyses for the β2AR Arg/Gly16 polymorphism and asthma risk.

![](pone.0101861.t002){#pone-0101861-t002-2}

  Variable      n    Case/Control         Arg16 vs Gly16          Arg16Arg vs Gly16Gly   Arg16Arg vs Gly16Gly/ Arg16Gly   Gly16Gly vs Arg16Arg/ Arg16Gly                                                                                                  
  ------------ ---- -------------- ----------------------------- ---------------------- -------------------------------- -------------------------------- -------- ----- ------------------------ -------- ----- ----------------------------- ---------- -----
  Overall       29    5595/15184    1.06\[1.01,1.12\] **0.02**         \<0.00001                      64%                   1.11\[1.02,1.21\] **0.02**     0.0007   52%   0.94\[0.87,1.02\] 0.12   0.0006   52%     1.10\[0.99,1.22\] 0.06      \<0.0001   58%
  Ethnicity                                                                                                                                                                                                                                               
  Asian         15    2882/2842     1.14\[1.05,1.23\] **0.001**         \<0.0001                      67%                  1.26\[1.12,1.43\] **0.0001**    0.008    53%   0.91\[0.81,1.04\] 0.16   0.005    55%   1.23\[1.06,1.44\] **0.008**    0.0002    66%
  Caucasiann    10    1726/10355      0.99\[0.91,1.08\] 0.89             0.002                        65%                     0.94\[0.80,1.10\] 0.45        0.09    40%   0.98\[0.87,1.10\] 0.72   0.003    64%     0.98\[0.82,1.17\] 0.81        0.03     52%
  Age                                                                                                                                                                                                                                                     
  Children      10    1817/3009       1.05\[0.97,1.15\] 0.23             0.0005                       70%                     1.11\[0.96,1.28\] 0.15       0.005    62%   0.96\[0.84,1.10\] 0.58   0.010    59%     1.06\[0.89,1.26\] 0.52       0.002     66%
  Adults        17    3582/11925      1.04\[0.98,1.11\] 0.22             0.003                        55%                     1.06\[0.95,1.18\] 0.32        0.08    35%   0.95\[0.86,1.05\] 0.31    0.01    50%     1.07\[0.94,1.22\] 0.32        0.02     47%

n, number of studies.

β2AR Gln/Glu27 and Asthma Risk {#s3c}
------------------------------

There were 22 studies investigating the association between Gln/Glu27 polymorphism and asthma risk ([Table S2](#pone.0101861.s002){ref-type="supplementary-material"}). One study [@pone.0101861-Santillan1] may be the main contributor to heterogeneity and has significantly influenced pooled results (discuss below). Therefore, it was not included in data synthesis process. Overall, no significant association was found in all genetic models when combined all other 21 studies ([Table 3](#pone-0101861-t003){ref-type="table"}). Age stratification showed significant associations in adults in allelic genetic model (OR = 1.10, 95% CI = 1.01∼1.19, p = 0.03) and additive genetic model (OR = 1.20, 95% CI = 1.07∼1.34, p = 0.002), but no association was found in ethnicity stratification ([Table 3](#pone-0101861-t003){ref-type="table"}).

10.1371/journal.pone.0101861.t003

###### Results of the pooled analyses and subgroup analyses for the β2AR Gln/Glu27 polymorphism and asthma risk.

![](pone.0101861.t003){#pone-0101861-t003-3}

  Variable      n    Case/Control         Gln27 vs Glu27         Gln27Gln vs Glu27Glu   Gln27Gln vs Glu27Glu/ Gln27Glu   Glu27Glu vs Gln27Gln/ Gln27Glu                                                                                          
  ------------ ---- -------------- ---------------------------- ---------------------- -------------------------------- -------------------------------- ----------- ----- ------------------------ ------ ----- ------------------------ ------ -----
  Overall       22    3363/12337      1.07\[0.99,1.15\] 0.09             0.03                        39%                     1.11\[1.01,1.23\] 0.03         0.005     49%   1.02\[0.89,1.18\] 0.77   0.64   0%    1.02\[0.87,1.20\] 0.80   0.89   0%
  Overall\#     21    3060/11733      1.02\[0.95,1.10\] 0.59             0.50                         0%                     1.03\[0.93,1.14\] 0.60         0.34      9%    1.02\[0.89,1.18\] 0.74   0.58   0%    1.01\[0.86,1.20\] 0.86   0.86   0%
  Ethnicity                                                                                                                                                                                                                                      
  Asian         9     1306/1286       1.10\[0.91,1.32\] 0.34             0.37                         8%                     1.18\[0.96,1.46\] 0.18         0.32      14%   0.72\[0.42,1.23\] 0.23   0.82   0%    0.75\[0.43,1.30\] 0.31   0.93   0%
  Caucasiann    7     1367/9948       1.03\[0.94,1.12\] 0.58             0.20                        30%                     1.02\[0.89,1.17\] 0.12         0.38      7%    1.05\[0.90,1.24\] 0.51   0.10   44%   1.06\[0.88,1.28\] 0.51   0.25   23%
  Age                                                                                                                                                                                                                                            
  Children      8      682/1104       0.96\[0.81,1.13\] 0.63             0.65                         0%                     0.86\[0.69,1.07\] 0.18         0.79      0%    1.21\[0.86,1.73\] 0.28   0.56   0%    1.00\[0.68,1.47\] 0.99   0.76   0%
  Adults        12    2485/10987    1.10\[1.01,1.19\] **0.03**          0.007                        57%                    1.20\[1.07,1.34\] 0.002       **0.002**   62%   1.01\[0.86,1.18\] 0.93   0.57   0%    1.05\[0.88,1.26\] 0.59   0.66   0%

\# Pooled result not included study of Santilan, A A\#, n, number of studies.

Heterogeneity exploration and sensitivity analysis {#s3d}
--------------------------------------------------

For β2AR Arg/Gly16 polymorphism, there were statistically significant heterogeneities in all genetic models when all eligible studies were combined ([Table 2](#pone-0101861-t002){ref-type="table"}). We thus performed subgroup analysis on the basis of age and ethnicity. Statistically significant heterogeneity remained shown in Asian and Caucasian population subgroup, children subgroup and adults subgroup ([Table 2](#pone-0101861-t002){ref-type="table"}). Therefore,we used Galbraith plots to graphically evaluate the source of heterogeneity. As showed in [Figure 2A](#pone-0101861-g002){ref-type="fig"}, four studies [@pone.0101861-Gao2], [@pone.0101861-Li1], [@pone.0101861-Saadi1], [@pone.0101861-Wang2] may be the main contributor to the heterogeneity in Asian population subgroup, and [Figure 2B](#pone-0101861-g002){ref-type="fig"} indicated that one study [@pone.0101861-Matheson1] maybe the main contributors to the heterogeneity in Caucasian population subgroup. In order to assess the reliablity of our meta-analysis, we further performed a sensitivity analysis through sequentially excluded individual study and similar result was obtained.

![Galbraith plots of the association between β2AR Arg16Gly polymorphism and asthma.\
A) Asian population subgroup; B) caucasian population subgroup. Four studies\# maybe the main contributors to the heterogeneity Asian population subgroup; One studies\# maybe the main contributors to the heterogeneity Asian population subgroup.](pone.0101861.g002){#pone-0101861-g002}

For β2AR Gln/Glu27 polymorphism, statistically significant heterogeneity were found in all genetic models, but quantitatively moderate heterogeneity with I^2^ values\<50% ([Table 3](#pone-0101861-t003){ref-type="table"}). Sensitivity analysis through sequentially excluded individual study shown that one study [@pone.0101861-Santillan1] maybe the main contributor to heterogeneity and has significantly influenced pooled results. Combined results excluding this study showed small heterogeneity for both Asian and Caucasian population ([Table 3](#pone-0101861-t003){ref-type="table"}).

Publication bias {#s3e}
----------------

For β2AR Arg/Gly16 polymorphism, as shown in [Figure 3A](#pone-0101861-g003){ref-type="fig"}, the shape of funnel plot revealed asymmetry to some extent. For β2AR Gln/Glu27 polymorphism, the shape of funnel plot did not indicate any evidence of significant asymmetry ([Figure 3B](#pone-0101861-g003){ref-type="fig"}). However, the Egger's test yielded no evidence of publication bias for β2AR Arg/Gly16 polymorphism (A vs G, p = 0.357), and Gln/Glu27 polymorphism (A vs G, p = 0.764).

![Funnel plot of publication bias for β2AR polymorphism under recessive genetic model.\
A) Arg/Gly16; B) Gln/Glu27. Funnel plot with pseudo 95% confidence limits was used.](pone.0101861.g003){#pone-0101861-g003}

Discussion {#s4}
==========

Asthma is a public health problem, affecting approximately 300 million people worldwide [@pone.0101861-Masoli1]. The mainstay of treatment for acute asthma includes inhaled short-acting β2-adrenergic receptor (β2AR) agonists, such as albuterol [@pone.0101861-Martinez1], [@pone.0101861-Fanta1]. There is mounting evidence that polymorphisms in the β2AR gene are associated with significant variability in response to short-acting β2-agonists (SABA). In adults, genetic variations in this receptor have also been linked to asthma severity [@pone.0101861-Holloway1], [@pone.0101861-Weir1]. In children, significant association was observed between favorable therapeutic response to inhaled β2-adrenergic agonists and the Arg/Arg phenotype at position 16 of the β2AR [@pone.0101861-Finkelstein1]. However, a large cohort study has shown that important β2AR gene polymorphisms are not main determinants of asthma incidence or prevalence in the British population [@pone.0101861-Hall1]. Therefore, conflicting data regarding the role of β2AR polymorphisms in asthma susceptibility and presentation has been reported.

We performed a systematic review and meta-analysis, including 37 studies involving 6648 asthma patients and 15943 controls, to investigate the associations between β2AR Arg/Gly16 and Gln/Glu27 polymorphisms and asthma. The combined results of 29 studies showed that A allele carriers of Arg/Gly16 polymorphism is strongly associated with asthma risk in the total population. Stratification by ethnicity revealed statistically significant association in the Asian population. Nonetheless, overall we failed to find any association between Gln/Glu27 polymorphisms and asthma risk for 21 eligible studies. Subgroup analysis on the basis of age and ethnicity showed significant associations in adults in allelic genetic model and recessive genetic model for Gln/Glu27. However, no association was found in Asian and Caucasian population subgroup based on ethnicity under any genetic model. Sensitivity analyses through sequentially excluding individual study yielded similar results in both β2AR Arg/Gly16 and Gln/Glu27 polymorphisms. In our study, we could not assess haplotype effects, which would have required genotype data that were unavailable in the published studies.

So far, three previous meta-analyses have been conducted to explore the function of β2AR gene polymorphisms in asthma [@pone.0101861-Thakkinstian1], [@pone.0101861-ContopoulosIoannidis1], [@pone.0101861-Migita1]. One of them shown that the Gly16 allele of the β2-adrenergic receptor gene increases the risk of nocturnal asthma, but does not alter the risk of mild asthma [@pone.0101861-ContopoulosIoannidis1]. The other reported that Gly16 may have a protective effect for children and Glu27 carriers may decrease the risk of asthma [@pone.0101861-Thakkinstian1]. The third one showed that ADRB2 does not contribute to susceptibility of asthma [@pone.0101861-Migita1]. Interestingly, our meta-analysis results are different from those of published meta-analysises, showing that Arg16 may increased the risk of asthma in total population, especially for Asian population. For Gln/Glu27, significant associations could only be found in adults in allelic genetic model and recessive genetic model. The inconsistency between the results of ours and published articles may be partly attributed to the following factors. First of all, while in our meta-analysis 37 studies (29 for Arg/Gly16 and 21 for Gln/Glu27, respectively) involving 6648 asthma patients and 15493 controls were included, Migita,O [@pone.0101861-Migita1] included 8 studies for Arg/Gly16 and 9 for Gln/Glu27, Thakkinstian,A and colleagues [@pone.0101861-Thakkinstian1] only included 12 studies for Arg/Gly16 and 12 for Gln/Glu27, Contopoulos-Ioannidis,D.G [@pone.0101861-ContopoulosIoannidis1] included 17 studies for Arg/Gly16 and 16 for Gln/Glu27 respectively. Second, some articles departing from HWE have been included in Contopoulos-Ioannidis D. G and Migita, O^,^s meta-analysis [@pone.0101861-ContopoulosIoannidis1], [@pone.0101861-Migita1]. Deviation from HWE is taken as an indication that the alleles are not segregating independently, either for genetic reasons or methodological reasons [@pone.0101861-Thakkinstian2]. Therefore, this may be a potential source of inconsistency between our study and other meta-analyses.

Genome-wide association study (GWAS) has been productive genotyping method to test a vast number of single nucleotide polymorphisms and assess their relations with complex diseases and phenotypes [@pone.0101861-Pearson1]. Since the first GWAS investigating susceptibility gene for asthma published in 2007 [@pone.0101861-Moffatt1], more than ten GWAS of asthma have been performed in Caucasian, Mexican, and African-ancestry populations [@pone.0101861-PinoYanes1], [@pone.0101861-Bouzigon1], [@pone.0101861-Tamari1] and more recently in Japan and Singapore of Asian populations [@pone.0101861-Andiappan1]--[@pone.0101861-Noguchi1]. Nevertheless, neither an individual GWAS study nor meta-analysis of GWAS has implicated ADRB2 the susceptibility gene for asthma. In our meta-analysis, we found that neither ADRB2 Arg/Gly16 nor ADRB2 Gln/Glu27 has significant association with asthma in Caucasian population, which further confirmed the results of previous published single GWAS and meta-analysis [@pone.0101861-PinoYanes1], [@pone.0101861-Bouzigon1], [@pone.0101861-Tamari1]. However, significant associations were found between ADRB2 Arg/Gly16 and asthma in Asian population, and this result contrasts with the results of studies recently conducted in Japan and Singapore [@pone.0101861-Andiappan1]--[@pone.0101861-Noguchi1], in which no single nucleotide polymorphisms in ADRB2 gene was found statistically significant. To date, GWAS studies for asthma have not been conducted in Chinese subjects, we are not sure whether the genomic findings of recent studies are applicable to Chinese. Therefore, in order to further clarify the role of ADRB2 gene in the pathogenesis of asthma, in the future, more GWAS should be conducted in Asian population, and especially Chinese considering its enormous population.

Several strengths of this meta-analysis could be listed as follows. First, we followed a rigorous protocol of systematic review, identifying data from 3 different databases comprehensively. Second, we have conducted subgroup analysis, sensitivity analysis and Galbraith plots to explore the source of heterogeneity, suggesting the reliability of our study. However, the results of our meta-analysis should be interpreted with caution due to some unavoidable limitations. First, potential heterogeneity and confounding factors may have affected the analysis. Statistically significant and quantitatively moderate--to--high heterogeneities were found in all genetic model for Arg/Gly16, even if we have found out the potential heterogeneity contributors. Second, publication bias might result in the loss of studies, which subsequently could affect the meta-analysis results. The shapes of funnel plots revealed slight asymmetry for Arg/Gly16 and we should pay attention to this point. Third, asthma is a heterogeneous group of conditions that result in recurrent, reversible bronchial obstruction [@pone.0101861-Martinez1]. As shown in [Table 1](#pone-0101861-t001){ref-type="table"} that the asthma definition varied among different articles and this may be a confounding factor. Case--control studies with clear diagnosis criteria and rigorous quality control are needed to conducted in the future. Fourth, most of the studies included in our meta-analysis were performed in Asians and Caucasians. Thus, our results may be applicable only to these ethnic groups. Fifth, although we have tried our best to contact the corresponding authors of published original papers and meta-analysis, we still cannot gain genotypes data of several studies. Sixth, so many tests have been conducted in our meta-analysis that it is not sure whether we have found something significant by chance in this process. Finally, asthma itself is a complex and multifactorial disease and potential interactions among gene-gene and gene-environment should be considered.

Conclusion {#s5}
==========

The present meta-analysis suggests that β2AR Arg/Gly16 polymorphism may be an important genetic factor in the overall risk for developing asthma, especially in Asian population, and Gln/Glu27 polymorphisms may be a contributor to asthma susceptibility for adults. GWAS or more case--control studies with explicit diagnosis criteria and rigorous quality control are needed to support this finding in various ethnic groups.
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